



## **Product Details**

| Product name:   | Anti-human TNFRSF8 / CD30 (brentuximab vedotin Biosimilar)              | SKU:               | BIO0866SM       |
|-----------------|---|--------------------|-----------------|
| Target Name:    | TNFRSF8 / CD30  | Size:              | 1 mg/5 mg/20 mg |
| Target Uniprot: | P28908  | Concentration:     | Lyophilized     |
| Clone#:         | brentuximab vedotin   | Isotype:           | Human IgG1      |
| Reactivity:     | Human   | Calculated M.W.:   | 145.48 kDa      |
| Application:    | ELISA, Bioactivity: FACS, Functional assay, Research in vivo            | Endotoxin:         | <0.001 EU/ug    |
| Formulation:    | 0.1M Pro, 20mM Arg, pH5.0   | Conjugation:       | MMAE(ADC)       |
| Storage:        | For long term storage, the produce should be stored at -20° C or lower. | Expression System: | СНО             |
| Reconstitution: | Dissolve with sterile ddH2O   | Purification:      | Protein A       |


### Data

## **Purity:SDS-PAGE**




Anti-TNFRSF8 / CD30 (brentuximab vedotin)on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

# **Purity:SEC-HPLC**




The purity of Anti-TNFRSF8 / CD30 (brentuximab vedotin) is 98.99%, determined by SEC-HPLC.

#### HIC



MMAE is conjugated by sulfhydryl coupling, the DAR value of Anti-TNFRSF8 / CD30 (brentuximab vedotin)antibody is 4.0.

## **Bioactivity:ELISA**



Immobilized human CD30 His at 2 ug/mL can bind Anti-TNFRSF8 / CD30 (brentuximab vedotin), EC50 is 0.006007ug/mL.